The authors thank Matt J. Dunn, PhD, and Jonathan T. Erichsen, PhD, for the technical advice they provided in setting up this study.
Supported by a PhD studentship from the Macular Society, United Kingdom (AMLH) and by the National Institute for Health Research Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology (RSA, DFG-H, PJM). DFG-H's chair at University College London is supported by funding from Glaucoma UK. The views expressed are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health. Conference presentation of this work at the 24th International Visual Field & Imaging Symposium (August 2022; Berkeley, CA) was supported by the Imaging and Perimetry Society in the form of a travel grant (AMLH).
Disclosure: A.M.L. Hunter, None; R.S. Anderson, visual field sensitivity testing (P), Alliance Pharmaceuticals (R); T. Redmond, visual field sensitivity testing (P); D.F. Garway-Heath, visual field sensitivity testing (P), Alcon Research Institute (F), Janssen (F, C), Santen UK (F, C), Novartis (F), CenterVue (R, C), Heidelberg Engineering (R), Oculus (R), Topcon (R), Allergan (C), Bausch & Lomb (C), Genentech (C), Omicron (C), Roche (C); P.J. Mulholland, visual field sensitivity testing (P), Heidelberg Engineering (F), LKC Technologies (F)